Your session is about to expire
← Back to Search
Observational (survey, biospecimen, medical record, CT) for Lung Cancer
N/A
Recruiting
Led By Stacy W Gray
Research Sponsored by City of Hope Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 5 years
Awards & highlights
Study Summary
This study examines the biological and social determinants that may increase the risk for lung cancer in patients and never-smoking individuals. Biological characteristics of a person can include their genetics and social determinants of a person can include their education, income, and environment, all of which can impact their health. Information collected in this study may help increase early detection of lung cancer.
Eligible Conditions
- Lung Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion, an average of 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Frequency of germline alterations
Other outcome measures
Associations between molecular phenotypes, social determinants of health, and the presence of lung cancer and related outcomes
Frequency of abnormal radiographic findings
LB test accuracy comparing LB genetic mutations to those found on next generation sequencing (NGS)
+4 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Observational (survey, biospecimen, medical record, CT)Experimental Treatment4 Interventions
Participants complete a survey over 40-45 minutes at baseline. Participants' medical records are also reviewed. Participants who have lung cancer but have not undergone treatment and participants not diagnosed with lung cancer (i.e., "unaffected"), undergo collection of blood samples at a scheduled clinical or research blood draw. Participants not diagnosed with lung cancer (i.e. "unaffected"), undergo a low-dose CT scan over 20 minutes.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 2
~1700
Computed Tomography
2017
Completed Phase 2
~2720
Find a Location
Who is running the clinical trial?
National Cancer Institute (NCI)NIH
13,680 Previous Clinical Trials
40,928,319 Total Patients Enrolled
City of Hope Medical CenterLead Sponsor
568 Previous Clinical Trials
1,924,460 Total Patients Enrolled
Stacy W GrayPrincipal InvestigatorCity of Hope Medical Center
2 Previous Clinical Trials
705 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Share this study with friends
Copy Link
Messenger